Cargando…

Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis

BACKGROUND: The prothrombotic defect factor V Leiden (FVL) may confer higher risk of ST‐segment–elevation myocardial infarction (STEMI), compared with non–ST‐segment–elevation acute coronary syndrome, and may be associated with more myocardial necrosis caused by higher thrombotic burden. METHODS AND...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmoodi, Bakhtawar K., Eriksson, Niclas, Vos, Gerrit J. A., Meijer, Karina, Siegbahn, Agneta, James, Stefan, Wallentin, Lars, ten Berg, Jurriën M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483522/
https://www.ncbi.nlm.nih.gov/pubmed/33998271
http://dx.doi.org/10.1161/JAHA.120.020025
_version_ 1784577149720592384
author Mahmoodi, Bakhtawar K.
Eriksson, Niclas
Vos, Gerrit J. A.
Meijer, Karina
Siegbahn, Agneta
James, Stefan
Wallentin, Lars
ten Berg, Jurriën M.
author_facet Mahmoodi, Bakhtawar K.
Eriksson, Niclas
Vos, Gerrit J. A.
Meijer, Karina
Siegbahn, Agneta
James, Stefan
Wallentin, Lars
ten Berg, Jurriën M.
author_sort Mahmoodi, Bakhtawar K.
collection PubMed
description BACKGROUND: The prothrombotic defect factor V Leiden (FVL) may confer higher risk of ST‐segment–elevation myocardial infarction (STEMI), compared with non–ST‐segment–elevation acute coronary syndrome, and may be associated with more myocardial necrosis caused by higher thrombotic burden. METHODS AND RESULTS: Patients without history of cardiovascular disease were selected from 2 clinical trials conducted in patients with acute coronary syndrome. FVL was defined as G‐to‐A substitution at nucleotide 1691 in the factor V (factor V R506Q) gene. Odds ratios were calculated for the association of FVL with STEMI adjusted for age and sex in the overall population and in the subgroups including sex, age (≥70 versus <70 years), and traditional cardiovascular risk factors. The peak biomarker levels (ie, creatine kinase‐myocardial band and high‐sensitivity troponin I or T) after STEMI were contrasted between FVL carriers and noncarriers. Because of differences in troponin assays, peak high‐sensitivity troponin levels were converted to a ratio scale. The prevalence of FVL mutation was comparable in patients with STEMI (6.0%) and non–ST‐segment–elevation acute coronary syndrome (5.8%). The corresponding sex‐ and age‐adjusted odds ratio was 1.06 (95% CI, 0.86–1.30; P=0.59) for the association of FVL with STEMI. Subgroup analysis did not show any differences. In patients with STEMI, neither the median peak creatine kinase‐myocardial band nor the peak high‐sensitivity troponin ratio showed any differences between wild‐type and FVL carriers (P for difference: creatine kinase‐myocardial band=0.33; high sensitivity troponin ratio=0.54). CONCLUSIONS: In a general population with acute coronary syndrome, FVL did not discriminate between a STEMI or non–ST‐segment–elevation acute coronary syndrome presentation and was unrelated to peak cardiac necrosis markers in patients with STEMI. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT00391872 and NCT01761786.
format Online
Article
Text
id pubmed-8483522
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84835222021-10-06 Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis Mahmoodi, Bakhtawar K. Eriksson, Niclas Vos, Gerrit J. A. Meijer, Karina Siegbahn, Agneta James, Stefan Wallentin, Lars ten Berg, Jurriën M. J Am Heart Assoc Brief Communication BACKGROUND: The prothrombotic defect factor V Leiden (FVL) may confer higher risk of ST‐segment–elevation myocardial infarction (STEMI), compared with non–ST‐segment–elevation acute coronary syndrome, and may be associated with more myocardial necrosis caused by higher thrombotic burden. METHODS AND RESULTS: Patients without history of cardiovascular disease were selected from 2 clinical trials conducted in patients with acute coronary syndrome. FVL was defined as G‐to‐A substitution at nucleotide 1691 in the factor V (factor V R506Q) gene. Odds ratios were calculated for the association of FVL with STEMI adjusted for age and sex in the overall population and in the subgroups including sex, age (≥70 versus <70 years), and traditional cardiovascular risk factors. The peak biomarker levels (ie, creatine kinase‐myocardial band and high‐sensitivity troponin I or T) after STEMI were contrasted between FVL carriers and noncarriers. Because of differences in troponin assays, peak high‐sensitivity troponin levels were converted to a ratio scale. The prevalence of FVL mutation was comparable in patients with STEMI (6.0%) and non–ST‐segment–elevation acute coronary syndrome (5.8%). The corresponding sex‐ and age‐adjusted odds ratio was 1.06 (95% CI, 0.86–1.30; P=0.59) for the association of FVL with STEMI. Subgroup analysis did not show any differences. In patients with STEMI, neither the median peak creatine kinase‐myocardial band nor the peak high‐sensitivity troponin ratio showed any differences between wild‐type and FVL carriers (P for difference: creatine kinase‐myocardial band=0.33; high sensitivity troponin ratio=0.54). CONCLUSIONS: In a general population with acute coronary syndrome, FVL did not discriminate between a STEMI or non–ST‐segment–elevation acute coronary syndrome presentation and was unrelated to peak cardiac necrosis markers in patients with STEMI. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifiers: NCT00391872 and NCT01761786. John Wiley and Sons Inc. 2021-05-17 /pmc/articles/PMC8483522/ /pubmed/33998271 http://dx.doi.org/10.1161/JAHA.120.020025 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Brief Communication
Mahmoodi, Bakhtawar K.
Eriksson, Niclas
Vos, Gerrit J. A.
Meijer, Karina
Siegbahn, Agneta
James, Stefan
Wallentin, Lars
ten Berg, Jurriën M.
Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
title Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
title_full Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
title_fullStr Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
title_full_unstemmed Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
title_short Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis
title_sort factor v leiden does not modify the phenotype of acute coronary syndrome or the extent of myocardial necrosis
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8483522/
https://www.ncbi.nlm.nih.gov/pubmed/33998271
http://dx.doi.org/10.1161/JAHA.120.020025
work_keys_str_mv AT mahmoodibakhtawark factorvleidendoesnotmodifythephenotypeofacutecoronarysyndromeortheextentofmyocardialnecrosis
AT erikssonniclas factorvleidendoesnotmodifythephenotypeofacutecoronarysyndromeortheextentofmyocardialnecrosis
AT vosgerritja factorvleidendoesnotmodifythephenotypeofacutecoronarysyndromeortheextentofmyocardialnecrosis
AT meijerkarina factorvleidendoesnotmodifythephenotypeofacutecoronarysyndromeortheextentofmyocardialnecrosis
AT siegbahnagneta factorvleidendoesnotmodifythephenotypeofacutecoronarysyndromeortheextentofmyocardialnecrosis
AT jamesstefan factorvleidendoesnotmodifythephenotypeofacutecoronarysyndromeortheextentofmyocardialnecrosis
AT wallentinlars factorvleidendoesnotmodifythephenotypeofacutecoronarysyndromeortheextentofmyocardialnecrosis
AT tenbergjurrienm factorvleidendoesnotmodifythephenotypeofacutecoronarysyndromeortheextentofmyocardialnecrosis